Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Evaxion A/S changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 15 | 17 | +2 |
| Shares | 1.43M | 1.54M | +114.4K (+8.0%) |
| Value | $6.81M | $5.74M | −$1.07M (−15.8%) |
New holders (5)
Institutions that held Evaxion A/S at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Rathbone Brothers plc | 45,723 | $170.1K | 0.00% |
| Renaissance Technologies LLC | 39,225 | $145.9K | 0.00% |
| Annis Gardner Whiting Capital Advisors, LLC | 30,000 | $111.6K | 0.02% |
| XTX Topco Ltd | 22,053 | $82.0K | 0.00% |
| Citadel Advisors LLC | 17,773 | $66.1K | 0.00% |
Sold out (3)
Institutions that held Evaxion A/S at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Point72 Asset Management, L.P. | 33,100 | $157.9K |
| Royal Bank of Canada | 3,900 | $19.0K |
| UBS Group AG | 3,217 | $15.3K |